ArticleBMJ public health2026
HIV care outcomes among transgender women compared with cisgender men and women: a retrospective cohort study in two hospitals in Paris, France.
Article in BMJ public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Transgender women are disproportionately affected by HIV worldwide, yet data on engagement in HIV care and treatment outcomes remain limited and inconsistent, particularly in European healthcare settings. We aimed to compare retention in care and virological outcomes among transgender women and cisgender people living with HIV. Methods: We conducted a retrospective cohort study using routinely collected clinical data from two tertiary hospitals in Paris, France. Adults living with HIV who initiated care between 2008 and 2018 were included and classified as transgender women, cisgender men or cisgender women. Loss to follow-up was defined as the absence of any clinical visit for a continuous 24-month period. Virological response was defined as the time to first HIV viral load <50 copies/mL. Patients with an undetectable viral load at entry into care were excluded from time-to-event analyses. Kaplan-Meier methods and Cox proportional hazards models were used to compare outcomes between groups. Results: A total of 129 transgender women, 1304 cisgender men and 523 cisgender women were included. The majority of transgender women (93.4%) were migrants from Latin America and their mean age at entry into care was lower than that of cisgender patients. After multivariable adjustment, no significant difference in loss to follow-up was observed between transgender women and cisgender men (aHR=1.06, 95% CI 0.72 to 1.63) or cisgender women (aHR=1.07, 95% CI 0.66 to 1.74). Time to virological response did not differ significantly between transgender women and cisgender men (aHR=1.04, 95% CI 0.85 to 1.30) or cisgender women (aHR=1.24, 95% CI 0.98 to 1.60) after adjustment. Conclusions: In this cohort from two Parisian hospitals, transgender women demonstrated retention in care and virological outcomes comparable to those of cisgender people living with HIV. These findings suggest that within supportive healthcare settings, HIV care outcomes among transgender women can be similar to those observed in cisgender populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.